Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.01M Buy
41,946
+2,188
+6% +$57.2K 1.23% 28
2026
Q1
$1.12M Buy
39,758
+1,544
+4% +$41.1K 1.76% 17
2025
Q4
$952K Buy
+38,214
New +$964K 1.53% 24

Other funds holding PFE

PCB Capital's PFE Position: Q2 2026 in Review

PCB Capital increased its Pfizer (PFE) stake by 5.5% in Q2 2026, buying an estimated $57.2K and bringing the position to 41,946 shares worth $1.01M. The position accounts for 1.23% of the portfolio, ranked #28.

PCB Capital first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.12M in Q1 2026. 850 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • PCB Capital held 41,946 shares of Pfizer worth $1.01M as of Q2 2026.
  • PCB Capital bought 2,188 Pfizer shares in Q2 2026, an estimated $57.2K.
  • Pfizer made up 1.23% of PCB Capital's portfolio in Q2 2026, its #28 holding.
  • PCB Capital first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • PCB Capital's Pfizer position peaked at $1.12M in Q1 2026.
  • 850 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on PCB Capital's 13F filing for Q2 2026, filed 20 Jul 2026.